Moreover, experimental data suggest that whereas Gal-3 could initially contribute to myocardial repair and the preservation of cardiac geometry and function, over the long term, Gal-3 activation could promote myocardial fibrosis and adverse ventricular remodeling [85]. The gene discussed is LGALS3; the disease is Myocardial fibrosis.